Read + Share
Kimura M, Usami E, Teramachi H, Yoshimura T, et al. Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment
of Metastatic Colorectal Cancer. Anticancer Res 2020;40:1605-1611.
PMID: 32132063
|
 |
|
Kimura M, Usami E, Teramachi H, Yoshimura T, et al. Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment
of Metastatic Colorectal Cancer. Anticancer Res 2020;40:1605-1611.
PMID: 32132063
|
|
|
|